Logo

NKGN

NKGen Biotech, Inc. Common Stock

NKGN

NKGen Biotech, Inc. Common Stock • NASDAQ
$0.04 ▲ 16.13% (+0.01)
Market Cap $4.48 M
52w High $0.96
52w Low $0.00
Dividend Yield 0%
P/E -0.02
Volume 200
Outstanding Shares 124.38M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2024 $652K ▲ $5.426M ▼ $-29.414M ▼ -4.511K% ▼ $-0.84 ▼ $-15.266M ▼
Q3-2024 $0 $6.788M ▼ $6.598M ▲ 0% $0.22 ▲ $7.402M ▲
Q2-2024 $0 $7.457M ▲ $-16.088M ▼ 0% $-0.67 ▼ $-15.115M ▼
Q1-2024 $0 $7.295M ▼ $-5.382M ▲ 0% $-0.25 ▲ $-3.987M ▲
Q4-2023 $0 $9.132M $-33.606M 0% $-1.54 $-32.861M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $0 ▼ $24K ▼ $0 ▼ $0 ▲
Q3-2024 $8K ▼ $14.995M ▼ $62.045M ▼ $-47.05M ▲
Q2-2024 $79K ▲ $15.648M ▼ $85.365M ▲ $-69.717M ▼
Q1-2024 $34K ▲ $16.316M ▼ $71.371M ▼ $-55.055M ▲
Q4-2023 $26K $16.481M $75.174M $-58.693M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2024 $-29.414M ▼ $-6.953M ▼ $-16K ▲ $6.967M ▲ $1.738M ▲ $-6.936M ▼
Q3-2024 $6.598M ▲ $-3.895M ▲ $-17K ▼ $3.82M ▼ $-92K ▼ $-3.912M ▲
Q2-2024 $-16.088M ▼ $-5.999M ▼ $-15K ▼ $6.059M ▲ $45K ▲ $-5.999M ▼
Q1-2024 $-5.382M ▲ $-4.034M ▲ $35K ▲ $4.007M ▲ $8K ▲ $-4.034M ▲
Q4-2023 $-33.606M $-6.939M $-18K $-1.803M $-8.76M $-6.957M

Five-Year Company Overview

Income Statement

Income Statement NKGN is a classic early-stage biotech story: no product revenue yet and a steady pattern of operating losses as it funds research and clinical trials. Losses have been fairly small in absolute terms but persistent over several years, and per‑share losses look large partly because of the company’s small size and capital structure around its SPAC listing. The picture is one of a company still firmly in the investment phase, with expenses dominated by R&D and corporate overhead, and no offsetting commercial income so far.

Balance Sheet

Balance Sheet The balance sheet looks thin and fragile. Total assets are modest, cash reported is minimal, and past periods show debt alongside negative or near‑zero equity, which signals accumulated losses and a tight capital base. This combination suggests limited balance‑sheet flexibility and a likely need for ongoing external funding to support operations. In short, there is not much cushion if trials are delayed, costs rise, or funding markets become less welcoming.

Cash Flow

Cash Flow Cash flows are consistently negative from operations, reflecting the cost of running trials and building the platform without revenue coming in. Free cash flow is also negative, though capital spending needs appear low for now. This indicates a straightforward but important dynamic: NKGN is burning cash at a steady pace and is dependent on outside capital—equity raises, debt, or partnerships—to keep advancing its programs. The key uncertainty is how easily and on what terms it can continue to finance that cash burn over time.

Competitive Edge

Competitive Edge Scientifically, NKGN is trying to carve out a differentiated position in natural killer (NK) cell therapies, especially by targeting neurodegenerative diseases like Alzheimer’s and Parkinson’s in addition to cancer. Its approach—super‑activated NK cells, an off‑the‑shelf allogeneic product that aims to avoid harsh pre‑conditioning, and proprietary manufacturing and cryopreservation—could offer real clinical and logistical advantages if trial results hold up. On the other hand, it is a small player in a field crowded with well‑funded oncology and neurodegeneration competitors, and its move from Nasdaq to the OTC market underlines both its early stage and the perceived risk level. Its competitive strength today rests mostly on potential rather than proven commercial traction.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of NKGN’s story. The company’s SNK platform, lead candidate SNK01 for Alzheimer’s and Parkinson’s, and allogeneic SNK02 for solid tumors all showcase a push to make NK therapies more potent, safer, and easier to administer. Fast Track status in Alzheimer’s adds credibility to the scientific rationale, and the early development of a CAR‑NK pipeline shows ambition to broaden into more targeted cancer therapies. At the same time, every program is still in clinical or preclinical stages, so the entire R&D portfolio is high‑risk, with success heavily dependent on upcoming trial readouts and the company’s ability to fund longer and larger studies.

Summary

NKGN is a very early‑stage, high‑risk biotech focused on next‑generation NK cell therapies for both brain diseases and cancer. Financially, it has no revenue, ongoing losses, a lean balance sheet, and steady cash burn, implying reliance on continued external capital. Strategically, it is pursuing a differentiated path in neurodegeneration and off‑the‑shelf NK therapies that, if successful, could set it apart from more conventional approaches. However, the lack of approved products, small scale, and challenging funding backdrop mean the company’s future hinges on a few critical factors: the strength of upcoming clinical data, its ability to secure partnerships or non‑dilutive funding, and its access to capital markets as it advances through more expensive stages of development.

NEWS

October 9, 2025 · 8:05 AM UTC

NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market

Read more

October 6, 2025 · 8:05 AM UTC

NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology

Read more

September 18, 2025 · 8:05 AM UTC

NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy Forum

Read more

September 9, 2025 · 8:05 AM UTC

NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets

Read more